Raporo ya kanseri iheruka ku isi ivuga ko kanseri y'ibihaha ikomeje kuba intandaro y'impfu ziterwa na kanseri ku isi hose, bingana na 18.7% by'abahitanwa na bo mu 2022. Abenshi muri bo ni kanseri y'ibihaha itari mito mito (NSCLC). Mugihe amateka ashingiye kuri chimiotherapie yindwara zateye imbere byatanze inyungu nke, paradigima yarahindutse.
Ivumburwa rya biomarkers zingenzi, nka EGFR, ALK, na ROS1, ryahinduye uburyo bwo kuvura, riva muburyo bumwe-bujyanye nuburyo bunoze bwibasira ibinyabuzima byihariye bya kanseri ya buri murwayi.
Nyamara, intsinzi yubuvuzi bwimpinduramatwara ishingiye rwose kubizamini bya geneti byukuri kandi byizewe kugirango hamenyekane intego nziza kumurwayi ukwiye.
Ibinyabuzima byingenzi: EGFR, ALK, ROS1, na KRAS
Biyomarkeri enye zihagarara nkinkingi mugupima molekuline ya NSCLC, iyobora ibyemezo byo kuvura umurongo wa mbere:
-EGFR:Imihindagurikire yimikorere igaragara cyane cyane mubanya Aziya, abategarugori, nabatanywa itabi. EGFR tyrosine kinase inhibitor (TKIs) nka Osimertinib yazamuye cyane umusaruro wabarwayi.
-ALK:“Guhindura diyama,” igaragara muri 5-8% by'imanza za NSCLC. ALK fusion-positif abarwayi bakunze kwitabira cyane ALK inhibitor, bakageraho igihe kirekire.
-ROS1:Kugabana ibintu bisa na ALK, iyi "mabuye y'agaciro" iboneka muri 1-2% by'abarwayi ba NSCLC. Uburyo bwiza bwo kuvura burahari, butuma bumenya neza.
-KRAS:Amateka afatwa nk "adakemurwa," ihinduka rya KRAS rirasanzwe. Iyemezwa rya vuba rya inhibitori ya KRAS G12C ryahinduye iyi biomarker kuva ku kimenyetso cyamenyekanye ihinduka intego igaragara, ihindura uburyo bwo kwita kuri iyi sisitemu yumurwayi.
MMT Portfolio: Yashizweho Kubyiringiro byo Gusuzuma
Kugira ngo byihutirwa gukenera kumenya neza biomarker, MMT itanga portfolio ya CE-IVD yaranzwe nigihe-nyacyoIbikoresho bya PCR, buri injeniyeri hamwe nubuhanga bugezweho kugirango yizere ikizere cyo gusuzuma.
1. Igikoresho cyo kumenya ihinduka rya EGFR
-Ikoranabuhanga rya ARMS ryazamuye:Abazamura umutungo bongera ihinduka ryihariye rya mutation.
-Gukungahaza Enzymatique:Kubuza endonuclease gusya ubwoko bwimiterere yimiterere yimiterere yinyamanswa, bikungahaza mutant bikurikirana kandi byongera ibisubizo.
-Guhagarika ubushyuhe:Intambwe yihariye yubushyuhe igabanya priming idasanzwe, ikomeza kugabanya ubwoko bwimiterere yinyamanswa.
-Inyungu z'ingenzi:Ntagereranywa sensibilité hasi kugeza1%mutant allele inshuro nyinshi, ubunyangamugayo buhebuje hamwe nigenzura ryimbere hamwe na enzyme ya UNG, nigihe cyihuta cyo guhinduka hafiIminota 120.
- Bihujwe nabyombi hamwe na biopsy byamazi.
- MMT EML4-ALK Igikoresho cyo Kumenya
- Ubushishozi bukabije:Kumenya neza ihinduka ryimiterere ihindagurika hamwe ntarengwa yo kumenya kopi 20 / reaction.
-Ubwiza buhebuje:Harimo ibipimo byimbere mugucunga inzira hamwe na enzyme ya UNG kugirango wirinde kwanduza karryover, wirinde neza ibyiza nibibi.
-Byoroshye & Byihuta:Ibiranga imikorere yoroheje, ifunze-tube yarangiye muminota igera kuri 120.
-Guhuza ibikoresho:Ihuza nibisanzwe bitandukanyeibikoresho nyabyo bya PCR, gutanga ibintu byoroshye kuri laboratoire iyo ari yo yose.
- MMT ROS1 Igikoresho cyo Kumenya
Ubushishozi bukabije:Yerekana imikorere idasanzwe mugushakisha byimazeyo nka kopi 20 / reaction yintego zo guhuza.
Ubwiza buhebuje:Gukoresha igenzura ryimbere ryimbere hamwe na enzyme ya UNG itanga ubwizerwe bwibisubizo byose, bigabanya ingaruka zo gutanga amakosa.
Byoroshye & Byihuta:Nka sisitemu ifunze-sisitemu, ntabwo bisaba intambwe igoye nyuma yo gukwirakwizwa. Intego kandi yizewe iboneka muminota igera kuri 120.
Guhuza ibikoresho:Yashizweho kugirango ihuze cyane hamwe nurwego rwimashini nyamukuru ya PCR, yorohereza kwinjiza byoroshye muri laboratoire ikora.
- MMT KRAS Igikoresho cyo Gutahura
- Ikoranabuhanga rya ARMS ryongerewe imbaraga, rikomezwa na Enzymatic Enrichment hamwe no guhagarika ubushyuhe.
- Gukungahaza Enzymatique:Koresha kubuza endonuclease kugirango uhitemo neza igogora ryubwoko bwimiterere yinyamanswa, bityo bikungahaye kuri mutant bikurikirana kandi bizamura cyane gukemura.
-Guhagarika ubushyuhe:Itangiza intambwe yihariye yubushyuhe kugirango itere kudahuza hagati ya mutant yihariye ya primers nubwoko bwinyamanswa, bikomeza kugabanya imiterere no kunoza umwihariko.
- Ubushishozi bukabije:Kugera kuri sensibilité ya 1% kuri mutant alleles, ukemeza kumenya ihinduka ryinshi ryimiterere.
-Ubwiza buhebuje:Kwinjiza imbere imbere hamwe na enzyme ya UNG irinda ibisubizo byiza nibibi.
-Akanama gashinzwe:Byashyizweho neza kugirango byorohereze kumenya ihinduka umunani ritandukanye rya KRAS ihindagurika ryibice bibiri gusa.
- Byoroshye & Byihuta:Tanga ibisubizo bifatika kandi byizewe muminota igera kuri 120.
- Guhuza ibikoresho:Ihuza neza nibikoresho bitandukanye bya PCR, itanga ibintu byinshi kuri laboratoire.
Kuki uhitamo igisubizo cya MMT NSCLC?
Byuzuye: Suite yuzuye kubinyabuzima bine bya NSCLC bikomeye.
Ikoranabuhanga risumba ayandi: Gutezimbere umutungo (Enzymatic Enrichment, Guhagarika Ubushyuhe) byemeza umwihariko no kumva neza aho bifite akamaro kanini.
Byihuse & Bikora: Uniform ~ iminota 120 protocole kuri portfolio yihutisha igihe-cyo-kuvura.
Byoroshye & Byoroshye: Bihujwe nurwego runini rwicyitegererezo hamwe nibikoresho nyamukuru bya PCR, kugabanya inzitizi zishyirwa mubikorwa.
Umwanzuro
Mubihe bya oncologiya isobanutse, kwisuzumisha molekulari ni compas iyobora inzira yo kuvura. Ibikoresho bya MMT byateye imbere byongerera imbaraga abaganga gushushanya neza imiterere yimiterere yimiterere ya NSCLC yumurwayi, bikingura ubushobozi bwo kurokora ubuzima bwo kuvura.
Contact to learn more: marketing@mmtest.com
Igihe cyo kohereza: Ugushyingo-05-2025